A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,444
- 试验地点
- 118
- 主要终点
- Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
研究概览
简要总结
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must:
- •Have been diagnosed with type 2 diabetes mellitus (T2DM)
- •Have HbA1c between ≥7.0% and ≤10.5%
- •Be on stable treatment with unchanged dose of metformin or metformin plus an SGLT-2 inhibitor for at least 3 months before screening
- •Be of stable weight (± 5%) for at least 3 months before screening
- •Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening
排除标准
- •Participants must not:
- •Have type 1 diabetes mellitus
- •Have had chronic or acute pancreatitis any time prior to study entry
- •Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment
- •Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss
- •Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level >3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if their ALT level is ≤3.0 the ULN for the reference range
- •Have an estimated glomerular filtration rate <45 mL/minute/1.73 m2 (or lower than the country specific threshold for using the protocol required dose of metformin per local label)
- •Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
- •Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
- •Have been taking any other diabetes medicines other than metformin, or metformin plus an SGLT-2 inhibitor during the last 3 months
- •Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
研究组 & 干预措施
5 mg Tirzepatide
5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
干预措施: Tirzepatide (Drug)
10 mg Tirzepatide
10 mg tirzepatide administered SC once a week.
干预措施: Tirzepatide (Drug)
15 mg Tirzepatide
15 mg tirzepatide administered SC once a week.
干预措施: Tirzepatide (Drug)
Insulin Degludec
Insulin degludec administered SC once a day.
干预措施: Insulin Degludec (Drug)
结局指标
主要结局
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
时间窗: Baseline, Week 52
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates Baseline + Pooled Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus SGLT-2i) + Treatment + Time + Treatment\*Time (Type III sum of squares).
次要结局
- Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score(Week 52)
- Change From Baseline in Body Weight(Baseline, Week 52)
- Percentage of Participants Achieving an HbA1c Target Value of <7%(Week 52)
- Change From Baseline in HbA1c (5 mg)(Baseline, Week 52)
- Change From Baseline in Fasting Serum Glucose(Baseline, Week 52)
- Percentage of Participants Who Achieved Weight Loss ≥5%(Week 52)
- Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values(Baseline, Week 52)
- Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 (Millimole/Liter (mmol/L))] or Severe Hypoglycemia(Baseline through Safety Follow-Up (Up to Week 56))